The rise of the AI-empowered patient: How direct-to-patient models will rewrite pharma commercialization

AI tools, at-home diagnostics, and new DTP platforms—from LillyDirect and PfizerForAll, to TrumpRx and Cost Plus Drugs—are turning patients into their own advocates and forcing pharma to rebuild commercialization from the patient backward.

From “Dr. Google” to the empowered patient OS

A decade ago, the “empowered patient” meant someone who Googled symptoms before a doctor’s visit. Today, that notion is almost quaint. Thirty-nine percent of Americans now trust AI chatbots to help navigate health care decisions¹; one in six adults uses AI for health information at least monthly—rising to one in four among those under 30.² Patients are no longer just searching. They are orchestrating their own care.

The AI-empowered patient uses copilots to interpret lab results, compare treatments, track biomarkers in real time, and navigate affordability pathways—all before stepping into a clinic. When paired with DTP platforms offering transparent pricing, integrated telehealth, and home delivery, these patients are becoming the primary strategists of their own care journeys. And pharma’s commercialization playbook—built on broadcast promotion and intermediated access—must shift to direct, service-centric, ecosystem-based models.

TABLE 1: The AI-empowered patient, by the numbers

Three forces creating the AI-empowered patient

Three converging forces—AI copilots, at-home diagnostics, and policy/pricing reform—are rapidly shifting the patient from passive recipient to active navigator. Each is accelerating on its own; together, they are reshaping who discovers a therapy, how they access it, and what they’re willing to pay.

AI & digital copilots:  AI adoption in health care has jumped from 3% to 22% of organizations in two years,³ with the FDA clearing over 1,000 AI-enabled devices⁷ and 66% of physicians now using health AI.⁸ For patients, these tools interpret medical notes, triage symptoms, and draft clinician questions—giving people specialist-level understanding of their own charts. One in eight adolescents already turns to AI for mental health advice, with 93% finding it helpful.⁹

Diagnostics & wearables:  At-home diagnostics and wearables are pushing care from episodic to continuous. The wearable medical device market exceeds $50 billion¹⁰ and over half of diagnostics experts expect 10–25% of all tests to be performed at home by 2035.¹¹ Critically, the drug pipeline itself demands this shift. In 2024, 38% of FDA-approved new molecular entities were personalized medicines requiring biomarker-guided treatment decisions—up from less than 10% a decade ago.⁶ In oncology, 40–48% of recent approvals target biomarker-defined populations.¹² As more therapies require genetic profiling, companion diagnostics, or continuous monitoring to prescribe and sustain, patient engagement is no longer optional—it is clinically necessary. This creates both a mandate and a barrier that pharma manufacturers must solve, or risk adoption failure for their most innovative therapies.

Policy & pricing reform: On the policy front, the Trump administration’s MFN initiative culminated in TrumpRx.gov, launched February 5, 2026 with 43 drugs from five manufacturers listed at launch and at least 16 MFN deals signed.¹³ Cost Plus Drugs now offers 2,000+ medications at transparent cost-plus-15% pricing.¹⁴ However, these new rails remain in early innings. Early data shows limited consumer awareness¹⁵; cash-pay-only models bypass insurance deductibles for the 85% of Americans with drug coverage¹⁶; and over half of listed drugs have cheaper generics available elsewhere.¹⁷ How TrumpRx evolves—whether it expands its formulary, integrates with insurance, and proves savings at scale—will shape government-facilitated DTP for years to come.

These forces are not merely informing patients—they are restructuring the economics of who discovers a therapy, how they access it, and what they’re willing to pay. The patient is no longer downstream of the system. They are becoming its center of gravity.

TABLE 2: Three converging forces driving the AI-empowered patient

Direct-to-patient 2.0: Beyond marketing to full-stack care

DTP has evolved from discreet, niche offers into integrated ecosystems spanning digital front doors, telehealth, payment, fulfillment, and support—a shift from persuasion to provision. The comparison below maps the major platforms, but three developments deserve attention.

LillyDirect, launched January 2024, is the canonical example. More than 1 million patients accessed treatments through the platform in 2025⁴; by Q2 2025, 35% of new Zepbound prescriptions flowed through its self-pay option¹⁸—making it the first pharma-owned platform to operationalize the full DTP stack: telehealth, e-prescribing, transparent cash pricing (from $299/month), and home delivery via Amazon Pharmacy and Walmart.

NovoCare Pharmacy (March 2025) has been equally significant for the weight-management category. Roughly 30% of all Wegovy prescriptions now flow through self-pay channels, and approximately 90% of new Wegovy pill prescriptions come through NovoCare⁵—demonstrating that when affordability and convenience converge, patients will bypass traditional pharmacy infrastructure at scale.

TrumpRx.gov represents a newer, still-evolving layer. Launched February 2026, the platform has begun connecting patients directly to manufacturer discounts under MFN pricing, and while adoption is early, the structural significance is clear: government, manufacturers, and patients transacting directly, bypassing traditional intermediaries.¹³

Together, these platforms are training patients to expect one-click, affordable access with integrated support—and shifting their mental model so that manufacturers, not intermediaries, become their primary counterpart.

TABLE 3: DTP platform landscape comparison

Opportunities and fault lines

The DTP era creates significant upside for pharma: shortened time-to-therapy, deeper adherence, margin recapture through transparent pricing, and rich real-time patient data. AI-powered chatbots in monitoring settings have driven engagement rates above 90% and adherence as high as 97%.¹⁹ But the risks are equally real. The table below maps both sides across six dimensions.

The equity challenge is particularly urgent: 29% of rural adults are shut out by the digital divide alone,²⁰ and AI diagnostic tools show up to 17% lower accuracy for minority patients.²⁰ Meanwhile, AI chatbots have virtually stopped including medical disclaimers—down from 26% of responses in 2022 to fewer than 1% in 2025²¹—even as the FDA tightens rules on AI-mediated promotion.

The AI-empowered patient is not a hypothetical persona—they’re already here. The question is whether industry uses DTP to truly support them, or simply to reroute revenue.

TABLE 4: Opportunities vs risks in the DTP era

How pharma commercialization must change

Yesterday’s model—HCP-centric detailing plus TV and digital DTC—is insufficient in a world where patients arrive with AI-generated understanding of their chart, expectations of transparent pricing, and the ability to bypass every intermediary. The shift is architectural, not incremental. The tables below map the new commercial model, the patient archetypes that should drive segmentation, and the KPIs that will replace legacy metrics.

TABLE 5: The commercial model shift: Yesterday vs tomorrow

Segmenting by therapy and patient archetype

DTP thrives in obesity, diabetes, migraine, dermatology, and sexual health. More complex categories require hybrid, provider-anchored models. But the critical segmentation layer is the patient—not just the therapeutic area.

TABLE 6: Three patient archetypes for DTP strategy

Metrics that matter

TABLE 7: Old KPIs vs new KPIs for DTP commercialization

The agency of the future: Woven’s role in the DTP revolution

This era demands partners who operate at the intersection of strategy, science, and creative. Woven Health Collective was built for exactly this moment.

1. Strategic partnership & DTP architecture. Woven maps portfolio-wide DTP gaps by therapy and patient archetype, then structures the right partner combinations—telehealth, logistics, payments, AI—to fill them. Whether a client needs to understand the complexities of the market to build a strategy, stand up a branded platform, or plug into NovoCare or Cost Plus Drugs, Woven architects the strategy and partnerships to make it real.

2. Creative storytelling & experience design. In the DTP era, the patient experience is the brand. Woven crafts narratives that position DTP as safer, more transparent, and more supportive—then designs the digital experiences that bring those narratives to life, from disease awareness campaigns that drive patients into DTP funnels to branded engagement platforms that sustain adherence and loyalty.

3. Science & clinical credibility. When patients can access drugs directly and AI generates health content at scale, trust becomes the scarcest currency. Woven grounds every execution in scientific rigor—ensuring content is evidence-based, clinically accurate, and designed to strengthen the physician-patient relationship, not bypass it.

4. Digital & AI expertise. Woven is a digital-first creative agency that serves as AOR for pharma brands across the full omnichannel stack—web, social, programmatic, and SEO/AEO/GEO. We extend that foundation into the AI layer DTP demands: helping partners navigate and integrate AI-driven partnerships and developing bespoke AI-powered patient tools—from symptom navigators to predictive engagement models. Woven’s recent partnership with Perplexity AI to bring AI-enabled services to our clients is one example of how we are actively building this capability, not just theorizing about it.

The agencies that lead in the DTP era will create awareness, engage patients, and drive empowered outcomes. That work starts with creative marketing—great storytelling that gets a patient to notice, to click, to take the first step. But in the DTP world, the impression is the beginning, not the end. The creative must connect to the strategic architecture: the partner ecosystem, the affordability pathway, the adherence program, the data loop that personalizes the next touchpoint. Woven does both—the creative that captures attention and the strategic infrastructure that turns it into therapy starts, sustained adherence, and measurable outcomes.

The future of pharma commercialization belongs to those who start with creative that moves patients and build systems that keep them moving. Woven is the agency of the future—strategy, science, and creative, woven together.

References

1. Censuswide / Drip Hydration. Survey of 2,000 Americans on AI and healthcare trust. 2025. Available at:
   https://driphydration.com/ai-health-survey/
2. KFF Health Misinformation Tracking Poll: Artificial Intelligence and Health Information. August 2025. Available at:
   https://www.kff.org/public-opinion/kff-health-misinformation-tracking-poll-artificial-intelligence-and-health-information/
3. Menlo Ventures, "2025: The State of AI in Healthcare." Available at:
   https://menlovc.com/perspective/2025-the-state-of-ai-in-healthcare/
4. Eli Lilly. Press Release . February 2026. Available at:
   https://investor.lilly.com/news-releases/news-release-details/lilly-reports-fourth-quarter-2025-financial-results-and-provides
5. Novo Nordisk. NovoCare. Available at:
   https://www.novocare.com
6. Personalized Medicine Coalition (PMC). "Personalized Medicine at FDA: Progress in 2024." May 2025. Available at:
   https://www.personalizedmedicinecoalition.org/Policy/Personalized-Medicine-at-FDA
7. FDA-Approved AI-Enabled Devices. July 2025. Available at:
   https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-enabled-medical-devices
8. DemandSage, "AI in Healthcare Statistics." December 2025. Available at:
   https://www.demandsaghttps://www.demandsage.com/ai-in-healthcare-stats/
9. RAND / Brown University / Harvard. "One in Eight Adolescents Use AI Chatbots for Mental Health Advice." JAMA Network Open. November 2025. Available at:
   https://sph.brown.edu/news/2025-11-18/teens-ai-chatbots 
10. Fortune Business Insights. Wearable Medical Devices Market, 2025–2034. Available at:
    https://www.fortunebusinessinsights.com/wearable-medical-devices-market-102020
11. Simon-Kucher. From pandemic spike to permanent shift: The rise of at-home diagnostics. Available at:
    https://www.simon-kucher.com/en/insights/pandemic-spike-permanent-shift-rise-home-diagnostics
12. Dou YN, et al. "Biomarkers for Precision Patient Selection in Cancer Therapy Approvals, 2011–2023." PubMed, May 2024. Available at:
    https://pubmed.ncbi.nlm.nih.gov/38747390/
13. White House Fact Sheet, February 5, 2026. Available at:
    https://www.whitehouse.gov/fact-sheets/2026/02/fact-sheet-president-donald-j-trump-launches-trumprx-gov-to-bring-lower-drug-prices-to-american-patients/
14. Becker's Hospital Review, "5 notable moves from Mark Cuban’s Cost Plus Drugs in 2025." June 2025. Available at:
    https://www.beckershospitalreview.com/pharmacy/5-notable-moves-from-mark-cubans-cost-plus-drugs-in-2025/
15. KFF Health Tracking Poll, February 24–March 2, 2026. Public Views on Prescription Drug Costs: Regulation, Affordability and TrumpRx. Available at:
    https://www.kff.org/public-opinion/public-views-on-prescription-drug-costs-regulation-affordability-and-trumprx/
16. STAT News, "TrumpRx has a fundamental flaw" February 5, 2026. Available at:
    https://www.statnews.com/2026/02/05/trumprx-prescription-drug-costs-flaws/
17. STAT News, "TrumpRx claims to offer the lowest prices. But many drugs have cheaper generics." Available at:
    https://www.statnews.com/2026/02/06/trumprx-discount-drug-website-undercut-by-cheaper-generics/
    
18. Eli Lilly / Walmart press release, October 29, 2025. Available at:
    https://investor.lilly.com/news-releases/news-release-details/lillydirect-and-walmart-pharmacy-launch-first-retail-pick-option
19. Cureus, "Chatbots as Catalysts for Improved Diagnosis, Treatment, and Patient Support." 2025. Available at:
    https://pmc.ncbi.nlm.nih.gov/articles/PMC12009506/
20. ScienceDirect, "Bridging the digital divide: artificial intelligence as a catalyst for health equity in primary care settings." 2025. Available at:
    https://www.sciencedirect.com/science/article/pii/S1386505625002680
21. MIT Technology Review, "AI companies have stopped warning you that their chatbots aren’t doctors." Available at:
    https://www.technologyreview.com/2025/07/21/1120522/ai-companies-have-stopped-warning-you-that-their-chatbots-arent-doctors/